Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
First Claim
1. A composition comprising a chimeric protein which comprises an MHC molecule and an immunoglobulin chain, wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide.
1 Assignment
0 Petitions
Accused Products
Abstract
To increase the effective affinity of soluble analogs of peptide/MHC molecules for their cognate ligands, divalent peptide/MHC complexes were constructed. Using a recombinant DNA strategy, DNA encoding the MHC class I was ligated to DNA coding for murine Ig heavy chain. MHC/Ig complexes were exploited to homogeneously load with peptides of interest. The results of flow cytometry demonstrated that the pepMHC/Ig complexes bound specifically with high affinity to cells bearing their cognate receptors.
pepMHC/Ig complexes are also useful in modulating effector functions of antigen-specific T cells. These pepMHC/Ig complexes are useful for studying TCR/MHC interactions and lymphocyte tracking and have uses as specific regulators of immune responses.
25 Citations
52 Claims
- 1. A composition comprising a chimeric protein which comprises an MHC molecule and an immunoglobulin chain, wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide.
- 15. A vector encoding a chimeric protein comprising an immunoglobulin heavy chain and an MHC molecule, wherein the immunoglobulin is not IgG-1, wherein the immunoglobulin heavy chain is C-terminal to the MHC molecule.
- 19. A composition comprising a chimeric protein which comprises an MHC molecule and an Ig chain, wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein the immunoglobulin chain is not an IgG heavy chain.
-
21. A composition comprising a cell in which a chimeric protein is bound to the surface of the cell, wherein the chimeric protein comprises an MHC molecule and an immunoglobulin chain;
- wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide.
- View Dependent Claims (22, 23)
-
24. A method for treating a patient suffering from an allergy, comprising:
administering to the patient at a dose sufficient to suppress a T cell response associated with an allergy of the patient a chimeric protein which comprises an MHC molecule and an immunoglobulin chain;
wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, and wherein the antigenic peptide is an antigen to which the patient has an allergic response.
-
25. A method for treating a patient who has received or will receive an organ transplant, comprising:
administering to the patient at a dose sufficient to suppress an immune response to the transplanted organ a chimeric protein which comprises an MHC molecule and an immunoglobulin chain;
wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, and wherein the antigenic peptide is an alloantigen.
-
26. A method for treating a patient suffering from an autoimmune disease, comprising:
administering to the patient at a dose sufficient to suppress an immune response associated with the autoimmune disease a chimeric protein which comprises an MHC molecule and an immunoglobulin chain;
wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, and wherein the antigenic peptide is one to which the patient expresses an autoimmune response.- View Dependent Claims (27, 28, 29, 30, 31)
-
32. A method for treating a patient having a tumor, comprising:
administering to the patient at a dose sufficient to induce or enhance an immune response to the tumor a chimeric protein which comprises an MHC molecule and an immunoglobulin chain;
wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, and wherein the antigenic peptide is a tumor-associated peptide.
-
33. A method for treating a patient having an infection caused by an infectious agent, comprising:
administering to the patient at a dose sufficient to induce or enhance an immune response to the infection a chimeric protein which comprises an MHC molecule and an immunoglobulin chain;
wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, wherein an antigenic peptide is bound to each MHC molecule, wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, and wherein the antigenic peptide is a peptide of an infectious agent.- View Dependent Claims (34, 35, 36, 37, 38, 39, 40)
-
41. A method of labeling antigen-specific T cells, comprising:
contacting a sample which comprises antigen-specific T cells with a chimeric protein;
wherein the chimeric protein comprises an MHC molecule and an immunoglobulin chain, wherein the chimeric protein associates to form molecular complexes comprising at least two chimeric proteins per complex, and wherein each MHC molecule within the molecular complex is bound to an identical antigenic peptide, whereby the antigenic peptide specifically binds to the antigen-specific T cells, thereby labeling the cells with the chimeric protein.- View Dependent Claims (42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)
Specification